Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Retapraz - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Retapraz

Approved

STANDARD

Retapraz

FUREN PHARMACEUTICAL GROUP CO., LTD🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 262db05deff4beee
Company: FUREN PHARMACEUTICAL GROUP CO., LTD
Type: Standard

Approval Details

Approval Id: 262db05deff4beee
Drug Approval Philippines Name: Retapraz
Product Name: Retapraz
Registration Number: DRP-5930-10
Brand Name: Retapraz
Generic Name: Omeprazole Sodium
Dosage Form: Lyophilized Powder For Injection
Dosage Strength: 40 mg
Manufacturer: FUREN PHARMACEUTICAL GROUP CO., LTD
Importer: AGLOBAL CARE, INC
Distributor: RETA DRUG
Issuance Date: 26 September 2023
Expiry Date: 05 December 2028
Classification: Prescription Drug (Rx)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

262db05deff4beee

Type

Standard

Back to Philippines FDA Approvals